Syndax Pharmaceuticals Inc (SNDX)
15.60
-0.35
(-2.19%)
USD |
NASDAQ |
Nov 21, 16:00
15.59
-0.01
(-0.06%)
After-Hours: 20:00
Syndax Pharmaceuticals Enterprise Value: 925.19M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 925.19M |
| November 20, 2024 | 955.06M |
| November 19, 2024 | 939.70M |
| November 18, 2024 | 968.72M |
| November 15, 2024 | 944.82M |
| November 14, 2024 | 1.027B |
| November 13, 2024 | 1.013B |
| November 12, 2024 | 977.25M |
| November 11, 2024 | 1.453B |
| November 08, 2024 | 1.455B |
| November 07, 2024 | 1.431B |
| November 06, 2024 | 1.416B |
| November 05, 2024 | 1.274B |
| November 04, 2024 | 1.210B |
| November 01, 2024 | 1.214B |
| October 31, 2024 | 1.202B |
| October 30, 2024 | 1.207B |
| October 29, 2024 | 1.221B |
| October 28, 2024 | 1.232B |
| October 25, 2024 | 1.193B |
| October 24, 2024 | 1.213B |
| October 23, 2024 | 1.175B |
| October 22, 2024 | 1.228B |
| October 21, 2024 | 1.259B |
| October 18, 2024 | 1.275B |
| Date | Value |
|---|---|
| October 17, 2024 | 1.290B |
| October 16, 2024 | 1.290B |
| October 15, 2024 | 1.278B |
| October 14, 2024 | 1.284B |
| October 11, 2024 | 1.225B |
| October 10, 2024 | 1.146B |
| October 09, 2024 | 1.156B |
| October 08, 2024 | 1.161B |
| October 07, 2024 | 1.151B |
| October 04, 2024 | 1.199B |
| October 03, 2024 | 1.188B |
| October 02, 2024 | 1.252B |
| October 01, 2024 | 1.290B |
| September 30, 2024 | 1.235B |
| September 27, 2024 | 1.175B |
| September 26, 2024 | 1.113B |
| September 25, 2024 | 1.101B |
| September 24, 2024 | 1.123B |
| September 23, 2024 | 1.094B |
| September 20, 2024 | 1.122B |
| September 19, 2024 | 1.153B |
| September 18, 2024 | 1.099B |
| September 17, 2024 | 1.105B |
| September 16, 2024 | 1.116B |
| September 13, 2024 | 1.195B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
115.30M
Minimum
Nov 22 2019
1.677B
Maximum
Jul 16 2024
809.84M
Average
776.60M
Median
Sep 14 2023
Enterprise Value Benchmarks
| Vertex Pharmaceuticals Inc | 109.46B |
| Moderna Inc | 7.852B |
| NovaBay Pharmaceuticals Inc | 2.798M |
| Palatin Technologies Inc | 15.96M |
| iBio Inc | 12.31M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -84.13M |
| Revenue (Quarterly) | 12.50M |
| Total Expenses (Quarterly) | 102.08M |
| EPS Diluted (Quarterly) | -0.98 |
| Profit Margin (Quarterly) | -673.0% |
| Earnings Yield | -23.27% |
| Normalized Earnings Yield | -23.27 |